TY  - JOUR
AU  - Bochtler, Tilmann
AU  - Hegenbart, Ute
AU  - Kunz, Christina
AU  - Benner, Axel
AU  - Seckinger, Anja
AU  - Dietrich, Sascha
AU  - Granzow, Martin
AU  - Neben, Kai
AU  - Goldschmidt, Hartmut
AU  - Ho, Anthony D
AU  - Hose, Dirk
AU  - Jauch, Anna
AU  - Schönland, Stefan O
TI  - Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
JO  - Amyloid
VL  - 21
IS  - 1
SN  - 1744-2818
CY  - Abingdon
PB  - Taylor & Francis Group
M1  - DKFZ-2017-00300
SP  - 9 - 17
PY  - 2014
AB  - Chromosomal aberrations of plasma cells are well established pathogenetic and prognostic factors in multiple myeloma, but their prognostic implication in systemic light chain (AL) amyloidosis is unclear. Therefore, the aim of this study was to identify prognostic cytogenetic risk factors by interphase FISH in a series of 103 consecutive AL amyloidosis patients treated uniformly with melphalan/dexamethasone as first-line therapy. Detection of gain of 1q21 was predictive for a poor overall survival (OS) (median 12.5 versus 38.2 months, p = 0.002). Hematologic event free survival (hem EFS) for gain of 1q21 was 5.0 versus 8.5 months in median (p = 0.08) and haematologic remission rates (≥VGPR) after three cycles were 5
KW  - Immunoglobulin Light Chains (NLM Chemicals)
KW  - Dexamethasone (NLM Chemicals)
KW  - Melphalan (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24455967
DO  - DOI:10.3109/13506129.2013.854766
UR  - https://inrepo02.dkfz.de/record/119669
ER  -